Accelerating Real-World Evidence Generation
Harness AI-driven methodology and longitudinal real-world evidence to quantify disease burden, demonstrate comparative effectiveness, and support global market access.
The Challenge
Bridging the Evidence Gap in CNS and Rare Disease
Rigorous Standards for Multilateral Stakeholders
Generating real-world evidence (RWE) that simultaneously satisfies the rigorous evidentiary standards of regulators, payers, and clinical stakeholders is a high-stakes, resource-intensive challenge.
Limitations of Foundational Claims Data
Demonstrating long-term value in CNS requires moving beyond simple claims data to a research-grade foundation that overcomes common pitfalls like missing cost data, insurance enrollment gaps, and fragmented patient journeys.
Evidentiary Barriers to Global Market Access
Securing favorable formulary positioning and international HTA submissions requires transparent, auditable, and representative data to accurately quantify the true clinical and economic burden of illness.
The Komodo Solution
Methodological Rigor for CNS Evidence Generation
Comprehensive Burden of Illness Studies
Uncover the true economic impact of PDP and Rett syndrome by leveraging proprietary cost imputation that achieves a 95%+ fill rate, capturing "hidden" costs from capitation or incomplete adjudication that standard datasets miss.
Transparent Comparative Effectiveness Research
Generate auditable, publication-ready CER backed by visible SQL and R code; every analytical step is exposed within Marmot to ensure findings are prepared for the most rigorous peer reviews and regulatory submissions.
Global Market Access & Evidence Velocity
Accelerate your path to international health authorities by reducing research timelines by 4 to 9 months; use MapEnhance to seamlessly integrate specialty lab and EHR data into your global evidence-gathering process.
Representative Longitudinal Patient Journeys
Build complete clinical narratives using automated enrollment tracking to bridge care gaps, grounded in a dataset that mirrors the U.S. Census for race and ethnicity (95–98% alignment) to ensure rare disease research is truly generalizable.
The Komodo Impact
Achieve a Velocity Advantage in Evidence Generation
The standard for RWE has evolved. Transition from manual data cycles to an AI-driven evidentiary backbone. Experience a higher standard of rigor for RWE generation.
Accelerated Time-to-Insight
Transform research cycles that traditionally consume weeks or months into minutes through automated cohort identification and descriptive statistics generation, enabling rapid iteration on evidence needs.
Standardized, Payer-Grade Cost Insights
Quantify the “Total Cost of Care” across inpatient, outpatient, and pharmacy settings using setting-specific reimbursement logic and proprietary cost imputation to support robust economic dossiers for international HTA bodies.
Publication-Ready Transparency
Every analysis in Marmot features visible code generation (SQL/R), enabling rapid survival modeling (Kaplan-Meier) and propensity score matching that is transparent, reproducible, and auditable for regulatory stakeholders and peer-reviewed journals.
Resources
Read more about how Komodo’s robust product suite can help you unlock your team’s expertise and accelerate decision-making across the enterprise.
AI Reliability Guide
Guide
Komodo Health’s HEOR Methodology
WHITE PAPER
Research Grade RWD & Analytics Solutions
ONE-PAGER
How Marmot Delivers Enterprise Wide ROI
Perspectives
Gain Your Velocity Advantage in Evidence Generation
The standard for RWE has evolved. Transition from manual data cycles to an AI-driven evidentiary backbone. Experience a higher standard of rigor for RWE generation.